What question did this study set out to answer?

To evaluate the safety and clinical efficacy of intravenous aminophylline when added to standard first-line therapies for acute asthma exacerbations in children and adolescents.

June 25, 2025Archives of Disease in Childhood

Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials

View Full Paper

Ask AI

Bookmark

Authors

KMKhalid MudawiQatar Airways (Qatar)AHAli HamudSidra Medical and Research Center CPColin PowellSt. Vincent's University Hospital

Discussion

Member takes

Implication

Meta-analysis reveals no significant clinical benefit but increased adverse effects with intravenous aminophylline in pediatric asthma, suggesting limited routine utility.

Key Points

To evaluate the safety and clinical efficacy of intravenous aminophylline when added to standard first-line therapies for acute asthma exacerbations in children and adolescents.
Systematic review and meta-analysis searching MEDLINE, Embase, CINAHL, Web of Science, and CENTRAL from 1966 to May 2024 (PROSPERO CRD42023405234).
Included 9 randomized controlled trials evaluating standard treatment with or without intravenous aminophylline across 466 pediatric participants.
Synthesized outcome data using random-effects models and assessed heterogeneity with fixed-effects models.
Aminophylline showed no significant benefit for asthma severity score (MD=0.13, 95% CI -0.79 to 1.06), hospitalisation rate (RR=0.66, 95% CI 0.27 to 1.59), intensive care admission (RR=0.73, 95% CI 0.51 to 1.05), intubation rate (RR=0.09, 95% CI 0.01 to 1.64, p=0.1), or length of stay (MD=-3.62, 95% CI -13.05 to 5.82).
Adverse gastrointestinal events were substantially higher with aminophylline, including elevated risks of emesis (RR=3.52, 95% CI 2.04 to 6.06) and nausea (RR=4.92, 95% CI 2.41 to 10.06).

Cite This Study

Mudawi et al. (2025) studied this question.

synapsesocial.com/papers/6aac8f248e423eacec6e02fd https://doi.org/10.1136/archdischild-2024-327492

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis reveals no significant clinical benefit but increased adverse effects with intravenous aminophylline in pediatric asthma, suggesting limited routine utility.

Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider